Determination of carbamazepine polymorphic contents in double-layered tablets using transmittance- and reflectance-near-infrared spectroscopy involving chemometrics.
BACKGROUND
Since polymorphs exhibit differences in chemical and physicochemical stability, characteristics, and dissolution rate of the bulk powder, they may significantly affect on the bioavailability of pharmaceutical compounds.


OBJECTIVE
The purpose of the present study is to establish a method for determining the carbamazepine (CBZ) polymorphic content of a double-layered tablet containing various ratios of forms I and III by using transmittance- and reflectance-near-infrared (TNIR and RNIR) spectroscopy involving chemometrics.


METHODS
Both TNIR and RNIR instruments were used to analyze both top (form I) and wire (form III) sides of the compacts, respectively. NIR spectra were analyzed to predict polymorphic content by a principal component regression analysis. NIR data of the tablets were divided into two wavelength ranges: between 860 and 1680 nm (FW), and 1245 and 1285 nm (NW).


RESULTS
The calibration models for polymorphic content based on TNIR had a linear relationship, but those based on RNIR did not. The accuracy of the calibration models suggested that the double-sided data set is more robust than the single-sided data set. Since the spectra of FW involved various information, the calibration models showed a linear correlation, but it is difficult to understand their model. In contrast, those of NW provided limited information on polymorphic forms making it very easy to understand the model.


CONCLUSIONS
Limiting the wavelength of the spectra is useful to help understand the calibration-complicated model.
Otsuka
Makoto
M
Research Institute of Pharmaceutical Sciences, Faculty of Pharmacy, Musashino University, Nishitokyo, Tokyo, Japan. motsuka@musashino-u.ac.jp
Fukui
Yuya
Y
D000927:Anticonvulsants / Q000737:chemistry*; D002138:Calibration; D002220:Carbamazepine / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D011208:Powders / Q000737:chemistry; D012044:Regression Analysis; D019265:Spectroscopy, Near-Infrared; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods; D014961:X-Ray Diffraction
D000927:Anticonvulsants; D011208:Powders; D013607:Tablets; D002220:Carbamazepine